Adenosine A2A Receptor

Migration, Crosslink

📖

Adenosine A2A Receptor

active

wiki page Created: 2026-04-02T07:20:05 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-entities-adenosine-a2a-receptor

📖 Wiki Page

entity1188 wordssynced 2026-04-02

Introduction

Adenosine A2A Receptor is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

The adenosine A2A receptor (A2AR) is a G protein-coupled receptor (GPCR) that plays a critical role in modulating dopaminergic signaling in the striatum and has emerged as a significant therapeutic target in [Parkinson's Disease](/diseases/parkinsons-disease). Antagonists of the A2A receptor, such as istradefylline, have demonstrated efficacy in reducing "off" time in Parkinson's Disease patients. [@schiffmann2007]

Overview

flowchart TD Adenosine_A2A_Receptor["Adenosine A2A Receptor"] -->|"modulates"| BDNF["BDNF"] Adenosine_A2A_Receptor["Adenosine A2A Receptor"] -->|"modulates"| Oligodendrogenesis["Oligodendrogenesis"] BDNF["BDNF"] -->|"interacts with"| Adenosine_A2A_Receptor["Adenosine A2A Receptor"] ZM_241385["ZM 241385"] -->|"inhibits"| Adenosine_A2A_Receptor["Adenosine A2A Receptor"] NTRK2["NTRK2"] -->|"interacts with"| Adenosine_A2A_Receptor["Adenosine A2A Receptor"] style Adenosine_A2A_Receptor fill:#4fc3f7,stroke:#333,color:#000

...

Introduction

Adenosine A2A Receptor is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.

The adenosine A2A receptor (A2AR) is a G protein-coupled receptor (GPCR) that plays a critical role in modulating dopaminergic signaling in the striatum and has emerged as a significant therapeutic target in [Parkinson's Disease](/diseases/parkinsons-disease). Antagonists of the A2A receptor, such as istradefylline, have demonstrated efficacy in reducing "off" time in Parkinson's Disease patients. [@schiffmann2007]

Overview

Mermaid diagram (expand to render)

The adenosine A2A receptor is encoded by the ADORA2A gene and is predominantly expressed in the striatum, olfactory tubercle, and nucleus accumbens of the brain["@fredholm2001"]. Within the basal ganglia, A2A receptors are highly enriched in striatopallidal "indirect pathway" [neurons](/entities/neurons), where they [@jenner2009]
modulate the activity of dopaminergic signaling in a manner opposite to D1 receptors. [@kase2006]

This receptor has attracted considerable attention in neurodegenerative disease research due to its: [@chen2013]

Strategic position in basal ganglia circuitry
Modulatory effects on dopaminergic transmission
Potential neuroprotective properties
Therapeutic utility in Parkinson's Disease

Structure and Pharmacology

Receptor Structure

The A2A receptor is a Class A GPCR consisting of: [@pinna2019]

Seven transmembrane domains (TM1-TM7)
Extracellular N-terminus with glycosylation sites
Intracellular C-terminus involved in G protein coupling and desensitization

The receptor binds adenosine as its endogenous ligand, with varying affinity depending on the receptor subtype. A2A receptors have higher affinity for adenosine compared to A2B receptors but lower affinity than A1 receptors.

Signaling Pathways

Upon activation by adenosine, A2A receptors couple to Gs/olf proteins, leading to:

Adenylyl Cyclase Activation: Increased cAMP production

Protein Kinase A (PKA) Activation: Phosphorylation of downstream targets

DARPP-32 Phosphorylation: Modulates dopaminergic signaling

ERK1/2 Activation: Involved in long-term neuronal adaptations

The Gs/olf coupling distinguishes A2A receptors from A1 receptors (Gi/o coupled) and creates a unique signaling profile in striatal neurons[@schiffmann2007].

Pharmacological Agents

| Agent | Type | Status | Application |
|-------|------|--------|--------------|
| Istradefylline (Nouriast) | A2A antagonist | Approved (Japan, US) | Parkinson's Disease "off" time reduction |
| Preladenant | A2A antagonist | Clinical trials | Parkinson's Disease |
| Vipadenant | A2A antagonist | Clinical trials | Parkinson's Disease |
| KW-6002 (Istradefylline) | A2A antagonist | Approved | Parkinson's Disease |
| Caffeine | Non-selective antagonist | Over-the-counter | Research, mild stimulation |

Role in Parkinson's Disease

Basal ganglia circuitry

In Parkinson's Disease, the loss of dopaminergic neurons in the substantia nigra pars compacta leads to:

Reduced D1 receptor activation in the direct pathway

Increased D2 receptor inhibition in the indirect pathway

Elevated A2A receptor activity due to increased adenosine tone

The net effect is excessive inhibitory output from the basal ganglia, producing the cardinal motor symptoms of Parkinson's Disease: bradykinesia, rigidity, and tremor.

A2A-D2 Receptor Interaction

A2A and D2 receptors exhibit antagonistic interactions in striatopallidal neurons:

D2 receptor activation inhibits adenylate cyclase, reducing neuronal firing
A2A receptor activation stimulates adenylate cyclase, increasing neuronal firing
A2A receptor blockade can indirectly enhance D2 receptor signaling

This crosstalk provides the therapeutic rationale for A2A antagonists in Parkinson's Disease[@jenner2009].

Therapeutic Benefits

A2A receptor antagonists provide several benefits in Parkinson's Disease:

Reduced "Off" Time: Decreasing the duration of OFF periods when medication wears off

Increased "On" Time: Extending ON periods with good motor function

Motor Symptom Improvement: Reducing bradykinesia and rigidity

Levodopa Sparing: May allow reduction of levodopa dose

Potential Neuroprotection: Preclinical evidence suggests disease-modifying potential

Neuroprotective Potential

Preclinical Evidence

Multiple preclinical studies have demonstrated neuroprotective properties of A2A receptor antagonists:

Mitochondrial Protection: A2A antagonists protect against mitochondrial toxins (MPTP, 6-OHDA)

Anti-inflammatory Effects: Reduce microglial activation and neuroinflammation

Anti-excitotoxic Effects: Attenuate glutamate-induced toxicity

[Autophagy](/entities/autophagy) Modulation: Enhance clearance of [alpha-synuclein](/proteins/alpha-synuclein) aggregates

Clinical Trials

Several clinical trials have investigated the neuroprotective potential of A2A antagonists:

Phase III trials of istradefylline showed significant reduction in OFF time
Preclinical-to-clinical translation studies suggest disease-modifying potential
Combination therapy with levodopa shows additive benefits

Expression in Disease States

Parkinson's Disease

A2A receptor expression and function are altered in Parkinson's Disease:

Increased receptor density in the striatum of PD patients
Altered adenosine metabolism in the basal ganglia
Therapeutic benefit from A2A antagonists correlates with disease stage

Other Neurodegenerative Conditions

| Condition | A2A Receptor Involvement |
|-----------|--------------------------|
| Huntington's Disease | Elevated A2A in striatum; antagonists may provide benefit |
| [Alzheimer's Disease](/diseases/alzheimers-disease) | Modulatory role in cognition; conflicting evidence |
| Multiple System Atrophy | Potential therapeutic target |
| Amyotrophic Lateral Sclerosis | Investigated for neuroprotection |

Genetic Studies

ADORA2A Gene Polymorphisms

Genetic variations in the ADORA2A gene have been associated with:

Parkinson's Disease risk: Certain haplotypes increase susceptibility
Caffeine response: Genetic variants modify caffeine's protective effects
Treatment response: Polymorphisms may predict A2A antagonist efficacy
Restless Legs Syndrome: Associated with ADORA2A variants

Notable Polymorphisms

rs5751876 (1976C>T): Associated with caffeine response and PD risk
rs35320474: Altered receptor function
rs2298383: Expression quantitative trait locus

Side Effects and Contraindications

Common Side Effects

Nausea
Dyspepsia
Headache
Insomnia
Orthostatic hypotension

Drug Interactions

A2A antagonists may interact with:

Anticoagulants: Potential bleeding risk
Antihypertensives: Additive blood pressure effects
CYP1A2 substrates: Metabolized by hepatic enzymes

Contraindications

Active gastrointestinal bleeding
Severe cardiovascular disease
Pregnancy (insufficient data)

Research Directions

Current research areas include:

Selective Agent Development: More selective A2A antagonists with better CNS penetration

Disease Modification: Clinical trials designed to assess neuroprotection

Combination Therapies: A2A antagonists with other PD treatments

Biomarkers: Identifying predictors of treatment response

Peripheral Targets: A2A receptors in immune cells and peripheral tissues

External Links

[PubChem - Adenosine A2A Receptor](https://pubchem.ncbi.nlm.nih.gov/)
[PD Beast - A2A Antagonists](https://www.pdbeast.com/)
[ClinicalTrials.gov - A2A Receptor Trials](https://clinicaltrials.gov/)

Brain Atlas Resources

Allen Human Brain Atlas: [Adenosine A2A Receptor expression search](https://human.brain-map.org/microarray/search/show?search_term=Adenosine+A2A+Receptor)
Allen Mouse Brain Atlas: [Adenosine A2A Receptor search](https://mouse.brain-map.org/search/index.html?query=Adenosine+A2A+Receptor)
Allen Cell Type Atlas: [Transcriptomic cell type reference](https://portal.brain-map.org/atlases-and-data/rnaseq)
BrainSpan Developmental Transcriptome: [Adenosine A2A Receptor developmental expression](https://www.brainspan.org/rnaseq/search/index.html?search_term=Adenosine+A2A+Receptor)

Background

The study of Adenosine A2A Receptor has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.

Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.

References

Fredholm BB, IJzerman AP, Jacobson KA, et al, International Union of Basic and Clinical Pharmacology (2001)

Schiffmann SN, Fisone G, Mones R, et al, Adenosine A2A receptors and basal ganglia physiology (2007)

Jenner P, Mori A, Hauser R, et al, Adenosine A2A receptor antagonists, movement disorders and Parkinson's Disease (2009)

Kase H, Kuriyama K, Ohno T, et al, Istradefylline (KW-6002): a novel selective adenosine A2A receptor antagonist for the treatment of Parkinson's Disease (2006)

Chen JF, Eltzschig HK, Fredholm BB, Adenosine receptors as drug targets—what are the challenges? Nat Rev Drug Discov (2013)

Pinna A, Adenosine A2A receptor antagonists in Parkinson's Disease: progress in clinical trials from the newly approved istradefylline to presynaptic A2A receptors (2019)

Pathway Diagram

The following diagram shows the key molecular relationships involving Adenosine A2A Receptor discovered through SciDEX knowledge graph analysis:

Mermaid diagram (expand to render)

📖 View canonical wiki page →

Related Entities

entities-adenosine-a2a-receptor

▸Metadataorigin_type: v1_polymorphic_backfill

slug	entities-adenosine-a2a-receptor
kg_node_id	None
entity_type	entity
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-9d3e2d543d4f
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'entities-adenosine-a2a-receptor'}
_schema_version	1

📊 Evidence Profile Foundational

Evidence Balance

+0%

Certainty

55%

Debates

0

Incoming

11

Outgoing

15

0 supporting 0 contradicting 0 neutral

View full evidence profile →

Public annotations (0)Annotate on Hypothes.is →

No public annotations yet.

📗 Cite This Artifact

Adenosine A2A Receptor

Introduction

Overview

Introduction

Overview

Structure and Pharmacology

Receptor Structure

Signaling Pathways

Pharmacological Agents

Role in Parkinson's Disease

Basal ganglia circuitry

A2A-D2 Receptor Interaction

Therapeutic Benefits

Neuroprotective Potential

Preclinical Evidence

Clinical Trials

Expression in Disease States

Parkinson's Disease

Other Neurodegenerative Conditions

Genetic Studies

ADORA2A Gene Polymorphisms

Notable Polymorphisms

Side Effects and Contraindications

Common Side Effects

Drug Interactions

Contraindications

Research Directions

See Also

External Links

Brain Atlas Resources

Background

References

Pathway Diagram

💬 Discussion